ES2227586T3 - Compuestos de piridin-tioalquilo alfa sustituido y alquileter como inhibidores de la transcriptasa viral inversa. - Google Patents

Compuestos de piridin-tioalquilo alfa sustituido y alquileter como inhibidores de la transcriptasa viral inversa.

Info

Publication number
ES2227586T3
ES2227586T3 ES96913306T ES96913306T ES2227586T3 ES 2227586 T3 ES2227586 T3 ES 2227586T3 ES 96913306 T ES96913306 T ES 96913306T ES 96913306 T ES96913306 T ES 96913306T ES 2227586 T3 ES2227586 T3 ES 2227586T3
Authority
ES
Spain
Prior art keywords
mmol
amino
chloro
ethyl
thiopyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96913306T
Other languages
English (en)
Spanish (es)
Inventor
Richard A. Nugent
Donn G. Wishka
Gary J. Cleek
David R. Graber
Stephen Thomas Schlachter
Michael J. Murphy
Joel Morris
Richard C. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2227586T3 publication Critical patent/ES2227586T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ES96913306T 1995-05-08 1996-05-03 Compuestos de piridin-tioalquilo alfa sustituido y alquileter como inhibidores de la transcriptasa viral inversa. Expired - Lifetime ES2227586T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43670895A 1995-05-08 1995-05-08
US436708 1995-05-08

Publications (1)

Publication Number Publication Date
ES2227586T3 true ES2227586T3 (es) 2005-04-01

Family

ID=23733510

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96913306T Expired - Lifetime ES2227586T3 (es) 1995-05-08 1996-05-03 Compuestos de piridin-tioalquilo alfa sustituido y alquileter como inhibidores de la transcriptasa viral inversa.

Country Status (26)

Country Link
US (1) US6043248A (OSRAM)
EP (2) EP1449835A3 (OSRAM)
JP (1) JPH11507017A (OSRAM)
KR (1) KR100445498B1 (OSRAM)
CN (2) CN1152022C (OSRAM)
AT (1) ATE275550T1 (OSRAM)
AU (1) AU712404B2 (OSRAM)
BR (1) BR9608265A (OSRAM)
CA (1) CA2216099C (OSRAM)
CZ (1) CZ293135B6 (OSRAM)
DE (1) DE69633332T2 (OSRAM)
ES (1) ES2227586T3 (OSRAM)
GE (1) GEP20002297B (OSRAM)
HU (1) HUP9801995A3 (OSRAM)
IL (1) IL118075A0 (OSRAM)
MX (1) MX9708582A (OSRAM)
NO (1) NO310287B1 (OSRAM)
NZ (1) NZ307089A (OSRAM)
PL (1) PL323240A1 (OSRAM)
PT (1) PT824524E (OSRAM)
RU (1) RU2167155C2 (OSRAM)
SK (1) SK150297A3 (OSRAM)
TW (1) TW450962B (OSRAM)
UA (1) UA56992C2 (OSRAM)
WO (1) WO1996035678A1 (OSRAM)
ZA (1) ZA963281B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526378A (ja) * 1997-09-25 2002-08-20 ファルマシア・アンド・アップジョン・カンパニー チオアルキル−アルファ−置換ピリミジン化合物
US6111111A (en) * 1997-10-23 2000-08-29 Kuraray Co., Ltd. Intermediates for producing pyridine derivatives
BR9913831A (pt) 1998-09-17 2001-05-29 Bristol Myers Squibb Co Processo para tratamento de arteriosclerose empregando um inibidor de ap2 e combinação
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
CA2376957A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
ES2755273T3 (es) * 2004-12-03 2020-04-22 Merck Sharp & Dohme Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación
SI1858861T1 (sl) * 2005-03-04 2010-10-29 Tibotec Pharm Ltd 2-(4-cianofenil)-6-hidroksilaminopirimidini, ki inhibirajo HIV
US7923056B2 (en) 2007-06-01 2011-04-12 Illinois Tool Works Inc. Method and apparatus for dispensing material on a substrate
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
SG186820A1 (en) * 2010-07-02 2013-02-28 Gilead Sciences Inc Napht- 2 -ylacetic acid derivatives to treat aids
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
KR101360587B1 (ko) * 2012-11-01 2014-03-10 현대자동차주식회사 스마트 도어 언록 시스템
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
NZ739226A (en) 2015-07-22 2022-11-25 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
KR20220101083A (ko) * 2019-10-04 2022-07-19 이난타 파마슈티칼스, 인코포레이티드 항바이러스 헤테로사이클릭 화합물
EP4093198A4 (en) * 2020-01-20 2024-01-24 Agrematch Ltd. Compositions for crop protection
CN114057707A (zh) * 2021-11-24 2022-02-18 上海应用技术大学 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法
CN118715205A (zh) * 2022-01-12 2024-09-27 艾福姆德尤股份有限公司 用于治疗与sting活性相关的病症的化合物和组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
US3940240A (en) * 1974-07-11 1976-02-24 Ina Seito Co., Ltd. Baking method and kiln for tile
ATE25255T1 (de) * 1983-05-05 1987-02-15 Heumann Ludwig & Co Gmbh Pyrimidin-thioalkylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel.
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPS62209062A (ja) * 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
HU203736B (en) * 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
ATE142621T1 (de) * 1989-12-28 1996-09-15 Upjohn Co Diaromatische substituierte verbindungen gegen den aids-virus
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
CA2109934C (en) * 1991-07-03 2002-12-10 Donna Lee Romero Substituted indoles as anti-aids pharmaceuticals
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
JP3077046B2 (ja) * 1992-08-31 2000-08-14 久光製薬株式会社 新規なキナゾリン誘導体
AU7636894A (en) * 1993-09-17 1995-04-03 Upjohn Company, The Substituted tetronic acids useful for treating hiv and other retroviruses
KR100354309B1 (ko) * 1993-11-12 2003-01-06 파마시아 앤드 업존 캄파니 피리미딘-티오알킬및알킬에테르화합물
AU2395095A (en) * 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
SK281683B6 (sk) * 1994-07-20 2001-06-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Tiopyridylové zlúčeniny a ich použitie

Also Published As

Publication number Publication date
NZ307089A (en) 1999-07-29
WO1996035678A1 (en) 1996-11-14
DE69633332T2 (de) 2005-09-22
TW450962B (en) 2001-08-21
NO975129L (no) 1998-01-07
CN1183773A (zh) 1998-06-03
PT824524E (pt) 2005-01-31
DE69633332D1 (de) 2004-10-14
EP1449835A3 (en) 2004-09-15
EP0824524A1 (en) 1998-02-25
PL323240A1 (en) 1998-03-16
GEP20002297B (en) 2000-11-25
JPH11507017A (ja) 1999-06-22
CA2216099A1 (en) 1996-11-14
CN1152022C (zh) 2004-06-02
ZA963281B (en) 1997-10-24
MX9708582A (es) 1998-02-28
NO975129D0 (no) 1997-11-07
AU712404B2 (en) 1999-11-04
BR9608265A (pt) 1999-02-02
HUP9801995A3 (en) 1999-04-28
KR100445498B1 (ko) 2004-11-16
NO310287B1 (no) 2001-06-18
RU2167155C2 (ru) 2001-05-20
IL118075A0 (en) 1996-08-04
SK150297A3 (en) 1998-10-07
US6043248A (en) 2000-03-28
AU5635396A (en) 1996-11-29
CN1535958A (zh) 2004-10-13
HUP9801995A2 (hu) 1999-03-29
UA56992C2 (uk) 2003-06-16
EP0824524B1 (en) 2004-09-08
HK1009446A1 (en) 1999-09-10
ATE275550T1 (de) 2004-09-15
CZ293135B6 (cs) 2004-02-18
CA2216099C (en) 2005-09-13
KR19990008400A (ko) 1999-01-25
EP1449835A2 (en) 2004-08-25
CZ349197A3 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
ES2227586T3 (es) Compuestos de piridin-tioalquilo alfa sustituido y alquileter como inhibidores de la transcriptasa viral inversa.
US20050148631A1 (en) Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE602004010206T2 (de) Dipeptidyl Peptidase Inhibitoren.
EP0633259B1 (de) Sulfonylaminopyrimidine, ihre Herstellung und Verwendung als Heilmittel
CA2132514C (en) Antiproliferative quinazolines
DE60110391T2 (de) Adenosin-rezeptor modulatoren
DE69427675T2 (de) Heterozyklische Verbindungen, ihre Herstellung und Verwendung
CN100473647C (zh) 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
ES2230316T3 (es) Derivados de pirrolopiridinona sustituidos utiles como inhibidores de la fosfodiesterasa.
US5981537A (en) Pyrimidine-thioalkyl and alkylether compounds
EP0510526A1 (de) Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide
PT1042293E (pt) Compostos de piridazina e piridina substituídos e as suas utilizações farmacêuticas
ES2217428T3 (es) Derivados de vinilpiridina sustituidos y medicamentos que los contienen.
JP2002523511A (ja) 新規化合物
US4698340A (en) Pyrimidine derivatives, processes for preparation thereof and composition containing the same
CA2955062A1 (en) Novel 2,5-substituted pyrimidines as pde inhibitors
WO2007050612A1 (en) 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace)
JPH0899961A (ja) ベンゼンスルホンアミド誘導体及びその製法
CN101374813A (zh) 作为ppar调节剂的芳基磺酰胺和磺酰基化合物及治疗代谢性病症的方法
JPS6165867A (ja) 新規ジヒドロピリジン
JPS6242983A (ja) （ベンズイミダゾ−ル−２−イル）−ピリジニウム化合物
CN101486683A (zh) 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
UA81271C2 (en) 2-pyridone derivatives as inhibitors of neutrophile elastase, process for the preparation thereof and pharmaceutical composition based thereon